US President Donald Trump has signed presidential decrees imposing tariffs as high as 100% on certain imported pharmaceuticals.
The tariffs are aimed at accelerating the relocation of manufacturing facilities to the United States.
However, for countries and with trade agreements with Washington, such as members of the European Union, Japan, and South Korea, a reduced tariff of 15% will apply.
The existing tariffs on metals will also be revised.
According to the White House, this is aimed at preventing companies from “artificially manipulating” their production prices to sell their goods more cheaply in the US.
